Brachytherapy

Papers
(The TQCC of Brachytherapy is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Editorial Board38
Editorial Board32
PO024929
PO032418
PO042517
PPP02 Presentation Time: 10:39 AM16
MPP02 Presentation Time: 4:09 PM16
PO041713
PO022713
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy13
BP08 Presentation Time: 5:03 PM13
BP02 Presentation Time: 4:09 PM12
PSOR12  Presentation Time: 5:25 PM12
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM12
PHSOR06 Presentation Time: 9:25 AM12
PPP03 Presentation Time: 10:48 AM12
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM12
PSOR03  Presentation Time: 12:10 PM11
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po10
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost10
PO9310
Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial10
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications10
PSOR8  Presentation Time: 12:05 PM10
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study10
PO3510
PO4710
GSOR04  Presentation Time: 12:15 PM9
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data9
PO219
Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy9
PO209
PO46  Presentation Time: 4:45 PM8
MSPP03  Presentation Time: 4:20 PM8
PP02  Presentation Time: 9:10 AM8
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM8
PSOR02  Presentation Time: 4:35 PM8
GSOR14  Presentation Time: 11:35 AM8
PHSOR04  Presentation Time: 12:45 PM8
PL02  Presentation Time: 1:45 PM8
PO108
PHSOR05  Presentation Time: 12:50 PM8
Table of Contents7
High-dose-rate brachytherapy for airway malignancy a single institution experience7
PP05  Presentation Time: 5:06 PM7
Increasing global access to brachytherapy: The ABS 300 in 10 initiative and ongoing international efforts7
Masthead7
The case for risk-stratified IORT for early breast cancer7
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma7
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life7
Table of Contents7
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?7
Determination of the optimal time for planning SAVI brachytherapy for APBI7
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer7
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma6
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes6
MSOR11 Presentation Time: 8:50 AM6
Partial breast irradiation: An updated consensus statement from the American brachytherapy society6
Comparison of novel shielded nasopharynx applicator designs for intracavitary brachytherapy6
PO02346
PO04216
Masthead6
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT6
HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients6
MSOR12 Presentation Time: 8:55 AM6
PL02 Presentation Time: 1:45 PM6
PO196
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy5
Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing5
PO02415
PO01195
PO915
PP02  Presentation Time: 10:09 AM5
PO155
Skin Posters PO07015
US-guided versus US-assisted tandem insertion for cervical cancer: A nomenclature proposal5
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review5
PSOR02 Presentation Time: 11:35 AM5
PO01095
PO02425
PO1145
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM5
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy5
Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer5
PO04245
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle5
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy5
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up5
PHSOR06  Presentation Time: 12:55 PM5
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer4
PO01104
PP05  Presentation Time: 11:36 AM4
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment4
PP04  Presentation Time: 9:47 AM4
PO864
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM4
GSOR09 Presentation Time: 12:10 PM4
PSOR7  Presentation Time: 12:00 PM4
PO524
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward4
A primer on time-driven activity-based costing in brachytherapy4
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent4
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting4
PO03204
MSOR11 Presentation Time: 5:50 PM4
PSOR3  Presentation Time: 11:40 AM4
PO534
Multipurpose ultrasound-based prostate phantom for use in interstitial brachytherapy4
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction4
PO33  Presentation Time: 10:30 AM4
PO40  Presentation Time: 4:45 PM4
PO02614
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital3
Dosimetric evaluation of a novel modular cell irradiation platform for multi-modality in vitro studies including high dose rate brachytherapy3
MSS11  Presentation Time: 4:35 PM3
PO04083
PP02  Presentation Time: 8:29 AM3
Table of Contents3
PO02583
Rule-based AI automated adaptive treatment planning for image guided cervical cancer brachytherapy3
Laminaria tent insertion in preplanning MRI for CT-based cervical cancer brachytherapy3
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer3
Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience3
PHSOR08  Presentation Time: 1:05 PM3
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method3
Masthead3
Actinium-225 Targeted Agents: Where Are We Now?3
Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer3
PO493
PO27  Presentation Time: 7:40 AM3
GSOR10 Presentation Time: 12:15 PM3
MSOR9 Presentation Time: 5:40 PM3
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer3
Demographic and clinical factors associated with variations in opioid administration using conscious sedation during HDR brachytherapy for cervical cancer3
PO02203
PO123
PO323
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment3
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry3
How do you do it?: Gynecologic brachytherapy best practices at high volume institutions within the United States and Canada3
PP04  Presentation Time: 11:27 AM3
Masthead3
MSPP05  Presentation Time: 4:40 PM3
PO03113
Wound complications and local recurrence do not differ when using interstitial brachytherapy versus external beam radiation therapy for soft tissue sarcoma3
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology3
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
PPP05 Presentation Time: 11:06 AM3
GYN Posters PO013
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer3
Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities2
Patient-specific cylinder templates for hybrid interstitial vaginal brachytherapy: Feasibility of automated 3-D design, 3D printing, and dosimetric outlook2
Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers2
PO04282
Comparing long-term sexual dysfunction across different uterine cancer treatment modalities2
PSOR05 Presentation Time: 11:50 AM2
GSOR23  Presentation Time: 12:20 PM2
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM2
Letter to the editor regarding “Reducing dose to rectum by placement of a rectum-emptying tube in cervical cancer patients treated with brachytherapy”2
MSOR7 Presentation Time: 5:30 PM2
MSS10  Presentation Time: 4:30 PM2
PO02332
PO02442
GSOR20  Presentation Time: 12:05 PM2
PO02552
PO822
PO04062
Editorial Board2
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy2
Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy2
Outcomes and comparison of dosimetric parameters between intracavitary (Fletcher) and combined intracavitary/interstitial (Utrecht) brachytherapy in locally advanced cervical cancer2
Improving plan quality in cervical brachytherapy using a simple knowledge-based prediction tool for OAR dose (D2cm3)2
Effects of a novel form of intraoperative radiation therapy on quality of life among patients with early-stage breast cancer2
PSOR06  Presentation Time: 12:25 PM2
Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer2
PO1122
HDR brachytherapy combined with external beam radiotherapy for unfavorable localized prostate cancer: A single center experience from inception to standard of care2
GSOR12 Presentation Time: 5:55 PM2
PO1082
PO02292
PSOR4  Presentation Time: 11:45 AM2
PO03142
Author Index2
PSA: Declining utilization of prostate brachytherapy2
PO1072
PO102
What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer?2
Role of the gel spacer in safely delivering whole pelvic radiation therapy without central shielding in computed tomography-based image-guided adaptive brachytherapy for uterine cervical cancer patien2
Brachytherapy for rectal and anal cancer: Where are we and current perspectives?2
Prospective validation of a machine learning model for applicator and hybrid interstitial needle selection in high-dose-rate (HDR) cervical brachytherapy2
Feasibility of internal-source tracking with C-arm CT/SPECT imaging with limited-angle projection data for online in vivo dose verification in brachytherapy: A Monte Carlo simulation study2
Ten-year treatment complication outcomes of radical prostatectomy vs external beam radiation vs brachytherapy for 1503 patients with intermediate risk prostate cancer2
GSOR09  Presentation Time: 12:40 PM2
Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer2
Development and promotion of a 3D-printed phantom model for ultrasound-guided caudal block followed by intracavitary/interstitial brachytherapy for gynecological cancer2
PO01112
Table of Contents2
PO092
GSOR06 Presentation Time: 5:25 PM2
PO052
PO03102
PP08  Presentation Time: 10:40 AM2
PL03 Presentation Time: 2:00 PM2
PO02562
PL04  Presentation Time: 2:15 PM2
PO02472
PO042
EM tracking with conventional CT tables: Quantifying and correcting for electromagnetic field distortion2
Systematic review of brachytherapy for symptom palliation2
Primary vaginal cancer treated with high-dose rate brachytherapy and intraprocedural magnetic resonance imaging1
Opioid consumption and pain in patients with gynecological cancer who underwent spinal anesthesia vs. general anesthesia for interstitial brachytherapy1
Quality control study of cervical cancer interstitial brachytherapy treatment plans using statistical process control1
Impact of de-escalating systemic therapy guided by 21-gene assay on locoregional recurrence after partial-breast irradiation1
GPP05 Presentation Time: 11:06 AM1
Prostate Posters PO04011
PO02461
Rectal sparing in prostate radiotherapy with combination-brachytherapy and hydrogel spacer1
Comparison of air kerma rate between the S7500 and S7600 xoft axxent sources1
Table of Contents1
PO191
BP04 Presentation Time: 4:27 PM1
PPP06 Presentation Time: 11:15 AM1
Mortality and postinterventional complications after ablative treatment of liver malignancies: A cohort study of 4374 patients1
PO421
Preoperative high-dose-rate brachytherapy for high-risk early-stage cervical cancer: Long-term clinical outcome analysis1
Comprehensive assessment of the effect of eye plaque tilt on tumor dosimetry1
PO02021
RadioPharm Posters PO05011
PO01021
PO03251
Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization1
Interstitial brachytherapy for gynecologic malignancies: Complications, toxicities, and management1
PO901
Table of Contents1
Saturday, July 13, 202411:30 AM - 12:30 PMPSOR01 Presentation Time: 11:30 AM1
Masthead1
MSOR10  Presentation Time: 5:30 PM1
Image-guided brachytherapy following external-beam radiation therapy for patients with inoperable endometrial cancer1
CivaSheet® use for soft tissue sarcoma: A single institution experience1
PO02401
PO04161
Masthead1
PO04341
PO111
Brachytherapy: Understanding the past to guide future practice1
PO30  Presentation Time: 10:30 AM1
PO1021
From patient to pioneer: The inspiring journey of Dr. Brian Moran1
PO03091
PO02631
0.080836057662964